Tuesday, July 1, 2025 7/1/2025

Technology Improving Success of Medication-Assisted Treatment in Primary Care

Award Number: R42DA050398
ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/30/2019
PERIOD OF PERFORMANCE END DATE: 08/31/2023

Group Awards By:

View Award Description

Technology Improving Success of Medication-Assisted Treatment in Primary Care - Project Abstract The opioid epidemic is the U.S.'s most widespread behavioral public health problem, with a higher number of deaths due to drug overdose in 2016 compared to deaths due to HIV at the peak of the AIDS epidemic. Medication assisted treatment (MAT) for opioid use disorder (OUD) is highly efficacious. However, only a fraction of persons with OUD access MAT, and treatment non-adherence and drop out is common. There is a dire need to improve systems to address these issues and to expand the use of MAT for many patients who are out of care. This R44 STTR application responds to RFA-DA-19-020, “HEAL Initiative: America's Startups and Small Businesses Build Technologies to Stop the Opioid Crisis.” It joins an outstanding scientific team at UCLA and a small business that has developed, Opioid Addiction Recovery Support (OARS) -- a software platform that by integrating with the Electronic Health Record (EHR) improves clinical management of patients by primary care providers (PCPs) treating patients with OUD using MAT. OARS platform uses a dashboard to show real-time measurement of patient achievements in recovery. It provides opportunities for patients to interact with their PCPs, allowing for better connection to and support from their PCPs. OARS platform features artificial intelligence to analyze information from the EHR and from patients to provide relapse risk assessment for patients receiving MAT for OUD, an innovation that sets OARS apart from other software solutions. The specific aim of Phase 1 of this STTR Fast Track proposal, is to modify the OARS platform for use in primary care settings by conducting interviews with PCPs (N=20) and their patients with OUD (N=40) in primary care settings to collect data on feasibility and acceptability of engaging with OARS to inform user- centered design of OARS. The specific aims of Phase 2 of this STTR Fast Track proposal are to: (1) employ a “stepped wedge” design to assess the effectiveness of OARS in improving opioid agonist treatment outcomes across 6 treatment programs (N=200 treated patients) and (2) evaluate sustainability and return on investment of OARS implementation across 6 treatment programs. A commercialization plan documents progress to date for OARS platform and presents a market plan to improve both scale-up and quality of MAT services delivered by PCPs in primary care, which is a major contribution to addressing the ongoing opioid epidemic.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2021	Q2I LLC	134 BIRCH DR	RINDGE	NH	03461	CHESHIRE	USA	Drug Use and Addiction Research Programs	000	3	3/8/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $594,298 )
2021	2021	Q2I, LLC	134 BIRCH DR	RINDGE	NH	03461	CHESHIRE	USA	Drug Use and Addiction Research Programs	001	3	8/24/2021	NON-COMPETING CONTINUATION	$594,298
2021	2019	Q2I, LLC	134 BIRCH DR	RINDGE	NH	03461	CHESHIRE	USA	Drug Use and Addiction Research Programs	000	1	12/15/2020	NEW	$0
														Subtotal = $594,298

Issue Date FY: 2020 ( Subtotal = $837,803 )
2020	2020	Q2I, LLC	134 BIRCH DR	RINDGE	NH	03461	CHESHIRE	USA	Drug Use and Addiction Research Programs	005	2	9/22/2020	EXTENSION WITH OR WITHOUT FUNDS	$125,135
2020	2020	Q2I, LLC	134 BIRCH DR	RINDGE	NH	03461	CHESHIRE	USA	Drug Use and Addiction Research Programs	003	2	7/24/2020	EXTENSION WITH OR WITHOUT FUNDS	$712,668
2020	2020	Q2I, LLC	134 BIRCH DR	RINDGE	NH	03461	CHESHIRE	USA	Drug Use and Addiction Research Programs	004	2	9/11/2020	EXTENSION WITH OR WITHOUT FUNDS	$0
2020	2019	Q2I, LLC	134 BIRCH DR	RINDGE	NH	03461	CHESHIRE	USA	Drug Use and Addiction Research Programs	002	1	7/23/2020	NEW	$0
2020	2019	Q2I, LLC	134 BIRCH DR	RINDGE	NH	03461	CHESHIRE	USA	Drug Use and Addiction Research Programs	001	1	12/20/2019	NEW	$0
2020	2019	Q2I, LLC	134 BIRCH DR	RINDGE	NH	03461	CHESHIRE	USA	Drug Use and Addiction Research Programs	000	1	11/21/2019	NEW	$0
														Subtotal = $837,803

Issue Date FY: 2019 ( Subtotal = $225,000 )
2019	2019	Q2I, LLC	134 BIRCH DR	RINDGE	NH	03461	CHESHIRE	USA	Drug Use and Addiction Research Programs	000	1	9/18/2019	NEW	$225,000
														Subtotal = $225,000

Grand Total All Awards = $1,657,101

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Technology Improving Success of Medication-Assisted Treatment in Primary Care

Award Number: R42DA050398

ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/30/2019

PERIOD OF PERFORMANCE END DATE: 08/31/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer